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BACKGROUND: In this open-label, international phase 2 study, the authors assessed the efficacy and safety of olmutinib in patients 
with locally advanced or metastatic non–small cell lung cancer (NSCLC) who had a confirmed T790M mutation and disease progres-
sion on previous epidermal growth factor receptor-tyrosine kinase inhibitor therapy. METHODS: Patients aged ≥20 years received 
once-daily oral olmutinib 800 mg continuously in 21-day cycles. The primary endpoint was the objective response rate (patients who 
had a confirmed best overall response of a complete or partial response), assessed by central review. Secondary endpoints included 
the disease control rate, the duration of objective response, progression-free survival, and overall survival. Adverse events were graded 
according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03). RESULTS: Overall, 162 pa-
tients (median age, 63 years; women, >60%) were enrolled from 68 sites in 9 countries. At the time of database cutoff, 23.5% of enrolled 
patients remained on treatment. The median treatment duration was 6.5 months (range, 0.03-21.68 months). Overall, 46.3% of patients 
(95% CI, 38.4%-54.3%) had a confirmed objective response (all partial responses). The best overall response (the objective response 
rate regardless of confirmation) was 51.9% (84 patients; 95% CI, 43.9%-59.8%). The confirmed disease control rate for all patients was 
86.4% (95% CI, 80.2%-91.3%). The median duration of objective response was 12.7 months (95% CI, 8.3-15.4 months). Estimated median 
progression-free survival was 9.4 months (95% CI, 6.9-12.3 months), and estimated median overall survival was 19.7 months (95% CI, 15.1 
months to not reached). All patients experienced treatment-emergent adverse events, and 71.6% of patients had grade ≥3 treatment-
emergent adverse events. CONCLUSIONS: Olmutinib has meaningful clinical activity and a manageable safety profile in patients with 
T790M-positive non–small cell lung cancer who received previous epidermal growth factor receptor-tyrosine kinase inhibitor therapy. 
Cancer 2021;127:1407-1416. © 2020 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society. 
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits 
use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or 
adaptations are made. 
KEYWORDS: epidermal growth factor receptor, non–small cell lung cancer, olmutinib, T790M, tyrosine kinase inhibitor.
INTRODUCTION
Lung cancer is the most commonly diagnosed cancer worldwide, and its incidence continues to grow.1 Typically, approx-
imately 85% of all lung cancers are diagnosed as non–small cell lung cancer (NSCLC).2
Globally, several epidermal growth factor receptor (EGFR)-targeting agents have been approved as first-line treat-
ments for patients with EGFR-mutant NSCLC.3,4 First-generation EGFR tyrosine kinase inhibitors (TKIs), such as 
erlotinib and gefitinib, have an excellent initial response against EGFR-activating mutations.5,6
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Although EGFR-TKIs represented a paradigm shift 
in the treatment of EGFR-mutant NSCLC, the emergence 
of tumor resistance after a median of 12 to 16 months 
was almost inevitable.7-9 The most common mechanism 
of acquired resistance (in up to 60% of patients) involves 
a secondary gatekeeper T790M mutation.8,10-17
Second-generation TKIs, such as afatinib and 
dacomitinib, have shown promising preclinical activities 
against T790M-positive tumors. However, their clini-
cal activity in T790M-positive NSCLC was poor, with 
dose-limiting toxicities caused by the simultaneous inhi-
bition of wild-type EGFR.18,19
Third-generation EGFR-TKIs, so-called EGFR mu-
tant-specific inhibitors (EMSIs), such as olmutinib, osimerti-
nib, rociletinib, naquotinib, and nazartinib, were designed 
to address the limitations of earlier drugs. Third-generation 
agents irreversibly block signaling by mutant EGFR   
(including T790M as well as EGFR activation mutations) 
but spare wild-type EGFR, thus providing potential efficacy 
in patients with an acquired T790M mutation after failing 
on first-generation or second-generation EGFR-TKIs.
Olmutinib, a small-molecule EMSI, has been eval-
uated in the treatment of patients who had NSCLC with 
T790M (acquired mutation).20,21 Preclinical studies re-
ported that olmutinib had excellent antitumor activity 
in various lung cancer cell lines with EGFR mutations 
(including T790M mutation) while producing minimal 
activity against wild-type EGFR.22 Clinical informa-
tion about olmutinib is available from a phase 1 study in 
healthy volunteers23 and from a phase 1/2 Korean study in 
patients with NSCLC who were pretreated with an EGFR-
TKI.24 Olmutinib 800 mg once daily was the maximum 
tolerated dose and was recommended for phase 2 evalua-
tion. In a phase 2 trial, the objective response rate (ORR) 
was 55.1% (95% CI, 42.6%-67.1%), most patients had 
tumor shrinkage relative to baseline (maximum shrinkage 
ranged from 27.7% to 100%), and the estimated median 
progression-free survival (PFS) was 6.9 months (95% 
CI, 5.6-9.7 months).24 Therefore, preclinical and clinical 
data indicate that olmutinib is effective in patients who 
have EGFR-mutant NSCLC with the T790M mutation. 
Olmutinib had a safety profile expected of an EGFR-
TKI, and most adverse events (AEs) were mild to moder-
ate.20,21,24,25 Furthermore, specific efficacy data from the 
phase 1/2 study suggested that olmutinib had significant 
clinical activity in patients with T790M-positive NSCLC 
after failing initial EGFR-TKI therapy and that reduced 
tumor volume was positively correlated with olmutinib 
exposure. When the phase 1/2 study was started, no tar-
geted therapies had been approved for T790M-positive 
NSCLC. Therefore, the current global trial was conducted 
to assess the efficacy and safety of second-line treatment 
(or later lines of treatment) with olmutinib in patients 
with locally advanced or metastatic NSCLC who had a 
confirmed T790M mutation and progressive disease (PD) 
on previous EGFR-TKI therapy.
MATERIALS AND METHODS
Study Design
This multicenter, single-arm, open-label, global phase 
2 study (ClinicalTrials.gov identifier NCT02485652) 
evaluated the efficacy, safety, and pharmacokinetics of ol-
mutinib in patients with T790M-positive NSCLC after 
failing an EGFR-TKI (see Supporting Fig. 1).
Patients were enrolled onto the study from July 24, 
2015 to July 5, 2016. All patients gave written informed 
consent. A tumor tissue sample taken after patients had PD 
during the last line of anticancer therapy (immediately before 
enrolment) was mandatory to confirm T790M mutation 
status at the central laboratory; the test kit used was theras-
creen EGFR RGQ polymerase chain reaction kit (Qiagen).
Patients received oral olmutinib 800 mg once daily, 
continuously in 21-day cycles, until they had radiologi-
cally confirmed PD (measured using Response Evaluation 
Criteria in Solid Tumors, version 1.1)26; patients contin-
ued to receive treatment if, in the investigator’s opinion, 
there was evidence of clinical benefit. An olmutinib dos-
age reduction to 600 mg once daily was allowed according 
to a protocol-defined dosage-reduction scheme. For pa-
tients who benefitted from olmutinib, a dosage reduction 
to 400 mg once daily was permitted, after discussion with 
the study sponsor, in cases of olmutinib-related toxicity.
Patients were seen weekly in cycle 1 (on days 1, 8, 
and 15), every 3 weeks during cycles 2 through 7 (on day 
1 of each cycle), and every 6 weeks thereafter (on day 1 
of alternate cycles). Tumor assessments were performed at 
screening and every 6 weeks (±7 days), as calculated from 
the date of first study drug administration, until they had 
objective radiologic PD. All computed tomography and 
magnetic resonance imaging scans were sent for indepen-
dent central review. All patients were evaluated at baseline 
using computed tomography and/or magnetic resonance 
imaging scans of the chest, abdomen, and pelvis. Patients 
who discontinued the study drug were followed for survival 
and poststudy anticancer treatment by telephone contact at 
least every 3 months until death or withdrawal of consent.
Study Patients
Patients were aged ≥20 years and had cytologically or 
histologically confirmed, locally advanced or metastatic 
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lung adenocarcinoma that was not amenable to curative 
surgery or radiotherapy. For inclusion, patients also had 
to have radiologically confirmed PD after at least 1 line 
of treatment with an EGFR-TKI, with or without prior 
chemotherapy, and a documented EGFR mutation (in-
cluding G719X, exon 19 deletion, L858R, and L861Q) 
associated with susceptibility to EGFR-TKIs. All patients 
had an Eastern Cooperative Oncology Group perfor-
mance status of 0 or 1 and a life expectancy ≥3 months, 
and all had centrally confirmed T790M mutation- 
positive tumors. All patients had to have at least 1 lesion 
(except in the brain) that was not previously irradiated 
and that could be accurately measured.
Principal exclusion criteria included: EGFR-TKI 
treatment (including erlotinib, gefitinib, and afatinib) 
within 8 days or 5-fold half-life, whichever was longer, of 
the first administration of study drug; previous treatment 
with afatinib with cetuximab or drugs targeting T790M 
mutant-positive EGFR; spinal cord compression; a his-
tory of any other malignancy (except for carcinoma in 
situ, nonmelanoma skin cancer, and superficial bladder 
tumors) in the past 5 years; psychiatric illness; and inter-
stitial lung disease or radiation pneumonitis.
Study Endpoints
The primary endpoint was the ORR, with a confirmed 
best overall response (BOR) of complete response (CR) or 
partial response (PR), as assessed by independent central 
review. The BOR was the defined as the best confirmed 
response based on all responses from the start of treat-
ment until PD, death, or new anticancer therapy (which-
ever occurred first). Tumor response was assessed every 6 
weeks after the first study drug administration until PD.
Secondary endpoints included the disease control 
rate (DCR), the duration of objective response (DOR), 
overall survival (OS), the time from first study drug 
administration until tumor progression, tumor shrink-
age (calculated as the absolute change and the percent 
change from baseline in the sum of tumor size at each 
assessment of tumor response), PFS, and safety. The 
DCR was defined as the proportion of patients with a 
documented CR, PR, or stable disease (for ≥5 weeks [6 
weeks ± 7 days [visit window]). The DOR was defined 
as the interval between the date of the first observation 
of a tumor response (CR or PR, which required subse-
quent confirmation ≥4 weeks after initial documenta-
tion of a response) and the date of PD or death from 
any cause, whichever occurred first. OS was the time 
from first study drug administration until death from 
any cause. Patients who remained alive were censored 
at their last follow-up date. Safety analyses were con-
ducted for all patients who had received at least 1 dose of 
study drug at the data cutoff according to the National 
Cancer Institute’s Common Terminology Criteria for 
Adverse Events, version 4.03.
Study Conduct
The study was conducted at 68 sites in 9 countries (see 
Supporting Table 1) and was reported in compliance with 
the study protocol and its amendments, the Declaration 
of Helsinki, local laws, the International Council for 
Harmonization–Good Clinical Practice, and the clini-
cal research organization’s standard operating procedures. 
The Institutional Review Board for the coordinating 
investigator (Keunchil Park, Samsung Medical Center) 
approved the study on July 28, 2015. The Institutional 
Review Board of the coordinating investigator (Pasi A 
Jänne, Dana-Farber Cancer Institute) gave a favorable 
opinion on March 28, 2016.
Statistical Analyses
A Simon 2-stage design27 was used to test the null hypoth-
esis that the ORR was ≤30% versus the alternative that 
the response was ≥45%.28 In the first stage, 49 patients 
were accrued: if there were ≤16 responses, then possible 
study discontinuation because of futility would be recom-
mended by the independent data monitoring committee. 
The primary efficacy analysis was planned when the first 
81 treated patients had had an assessment of the primary 
endpoint or had been prematurely withdrawn: the null hy-
pothesis would be rejected if ≥33 responses were observed. 
This design was expected to yield a 1-sided type I error rate 
of 2.5%, with a power of 80%, when the true response 
rate was 45%. To provide further safety data as well as a 
supportive efficacy evaluation, recruitment was planned to 
continue until 150 patients had entered the study.
The ORR, DCR, and BOR were reported with 
category counts (percentages and 95% CIs). All time-
to-event endpoints (ie, PFS, OS, DOR) were evaluated 
using Kaplan-Meier estimates, and curves were gen-
erated based on these estimates. For tumor shrinkage, 
percent changes from baseline in sums of tumor size 
at each assessment were calculated. ORR, DCR, DOR, 
PFS, and OS also were summarized according to the 
number of previous lines of anticancer therapy, back-
ground EGFR mutation type, and the presence of base-
line brain metastases.
Safety data were analyzed using descriptive statistics. 
Treatment-emergent AEs (TEAEs) were defined as those 
starting or worsening in severity any time between the 
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date of first study drug administration and 28 days after 
the last study drug administration.
Circulating Cell-Free DNA Analysis
Plasma samples were collected (optional consent) from 
enrolled patients at every tumor assessment and limited 
as pairs (screening and after treatment). Circulating cell-
free DNA (cfDNA) was analyzed using a targeted next-
generation sequencing (NGS) assay (Axen Cancer Panel 
1; Macrogene) at a Clinical Laboratory Improvement 
Amendments (CLIA)-certified, College of American 
Pathologists-accredited laboratory (Macrogene). Briefly, 
cfDNA (minimum, 20 ng) was isolated and enriched 
using targeted hybridization capture for library prepara-
tion, followed by sequencing on the Illumina HiSeq plat-
form, with genetic alterations annotated by the Genome 
Analysis Toolkit, version 3 (GATK3) (Broad Institute).
RESULTS
In total, 486 patients were screened (Fig. 1), of whom 
162 were enrolled in the study (the full-analysis set) (see 
Supporting Table 1). Approximately 40% of patients 
failed screening because of the absence of T790M. Of the 
162 patients enrolled, 38 (23.5%) remained on treatment 
at the time of database cutoff. The principal reasons for 
treatment discontinuation were PD (38.9% of patients), 
AEs (16%), and patient withdrawal (9.3%). The median 
study duration, including the follow-up period, at data-
base cutoff was 12.7 months (range, 0.03-21.7 months).
Baseline characteristics for the safety set are listed 
in Table 1. The median patient age was 63 years, >60% 
of patients were women, and all patients had an Eastern 
Cooperative Oncology Group performance status ≤1. 
Approximately one-third of patients were former smok-
ers, slightly more than one-half of all patients had stable 
brain metastases, >60% had the exon 19 del EGFR mu-
tation, and all had the T790M mutation. Approximately 
80% of patients had received 1 or 2 previous lines of sys-
temic therapy, including EGFR-TKIs.
Overall, the median treatment duration was 6.5 
months (range, 0.03-21.68 months). Fifty-four patients 
(33.3%) had an olmutinib dosage reduction (until they 
developed PD) to 600 mg daily, and 12 (7.4%) had a 
reduction to 400 mg daily.
Seventy-five patients in the safety set (46.3%; 95% 
CI, 38.4%-54.3%) had a confirmed objective response 
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(all PRs), as assessed by independent central review. 
Sixty-five patients had stable disease (40.1%), 8 had PD 
(4.9%), and the confirmed DCR was 86.4% (95% CI, 
80.2%-91.3%) (Table 2). The best response (ORR re-
gardless of confirmation) was 51.9% (84 patients; 95% 
CI, 43.9%-59.8%).
A waterfall plot of the maximum percentage tumor 
shrinkage, assessed by independent review, is shown in 
Figure 2. Most patients had tumor shrinkage, and the me-
dian DOR was 12.7 months (95% CI, 8.3-15.4 months).
In the safety set, 83 patients (51.2%) had a PFS 
event, and the estimated median PFS was 9.4 months 
(95% CI, 6.9-12.3 months). In total, 54 patients (33.3%) 
had an OS event, and the estimated median OS was 19.7 
months (95% CI, 15.1 months to not reached) (Fig. 3).
In patients who had baseline brain metastases (n = 
83), the confirmed ORR was 49.4% (95% CI, 38.2%-
60.6%) and the DCR was 86.8% (95% CI, 77.5%-
93.2%); corresponding values in patients without brain 
metastases at baseline (n = 79) were 43.0% (95% CI, 
31.9%-54.7%) and 86.1% (95% CI, 76.5%-92.8%), 
respectively. The median PFS for patients who had base-
line brain metastases was 8.1 months (95% CI, 5.6-10.8 
months) compared with 11.2 months (95% CI, 7.2-15.2 
months) for patients without baseline brain metastases 
(P = .076; log-rank test) (see Supporting Table 2).
In the dosage-reduction subgroups, the median 
treatment duration until the first dose reduction (from 
olmutinib 800 mg daily to 600 mg daily) was 1.4 months 
(95% CI, 0.3-15.2 months) and the second dose reduc-
tion (from olmutinib 600 mg daily to 400 mg daily) was 
3.8 months (95% CI, 0.4-12.3 months). No significant 
differences were noted between the 3 groups regarding 
confirmed ORRs and confirmed DCRs (see Supporting 
Table 3). Regarding other subgroup analyses, no major 
between-group differences in efficacy results were noted 
between patients who had received 1 or ≥2 previous lines 
of chemotherapy (see Supporting Table 4).
All patients experienced TEAEs, and 71.6% had 
grade ≥3 TEAEs. Drug-related TEAEs were reported in 
152 patients (93.8%) and the most frequently reported 
were diarrhea (38.3%), nausea (27.2%), hyperkerato-
sis (26.5%), and rash (26.5%). Grade ≥3 drug-related 
TEAEs were reported in 78 patients (48.2%), and the 
most frequently reported were palmar-plantar erythro-
dysesthesia syndrome (4.3%), rash (4.3%), diarrhea 
(3.1%), increased alanine aminotransferase (3.1%), and 
hyperkeratosis (2.5%). One case of grade 5 toxic epider-
mal necrolysis (TEN) and 2 cases of grade 3 interstitial 
lung disease were reported (Table 3; see also Supporting 
Table 5). Overall, 61 patients (37.7%) had AEs that led to 
olmutinib dosage reductions (from 800 to 600 mg, 51 pa-
tients; from 600 to 400 mg, 10 patients), and 28 patients 
(17.3%) had AEs that led to treatment discontinuation; 
in 14 patients (8.6%), TEAEs that led to treatment dis-
continuation were considered drug-related, which most 
TABLE 1. Baseline Characteristics for the Safety 
Set, n = 162
Characteristic No. of Patients (%)

















T790M mutation at baselineb
Positive 162 (100.0)
Negative 0 (0.0)





Abbreviations: ECOG, Eastern Cooperative Oncology Group; EGFR, epider-
mal growth factor receptor.
aPatients categorized as unclassified were enrolled based on documented 
EGFR mutation status, but there was no information about specific mutation 
subtypes.
bCentral confirmation was performed using the Therascreen EGFR RGQ poly-
merase chain reaction kit (QIAGEN).
cSystemic therapy included EGFR tyrosine kinase inhibitors. Adjuvant and 
neoadjuvant chemotherapy were not counted.
TABLE 2. Overall Response by Independent Central 
Review for the Safety Set, n = 162
Parameter
Response Rate, 
No. (%) 95% CI
Overall response rate (regardless of 
being confirmed)
84 (51.9) 43.9-59.8
Overall response rate (confirmed) 75 (46.3) 38.4-54.3
Partial response 75 (46.3)
Stable disease 65 (40.1)
Disease control rate (confirmed) 140 (86.4) 80.2-91.3
Progressive disease (PD) 8 (4.9)
Non-CR/Non-PD 2 (1.2)
Not evaluable 12 (7.4)
Abbreviation: CR, complete response.
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frequently comprised palmar-plantar erythrodysesthesia 
syndrome (2.5%), rash (1.2%), and pneumonia (1.2%). 
In total, 79 patients (48.8%) had serious AEs and, in 30 
patients (18.5%), these AEs were classified as drug-re-
lated (the most frequent were diarrhea [2.5%] and py-
rexia [2.5%]). Twelve patients had fatal AEs, but most of 
these events were not drug-related, except 1 case of TEN. 
Subgroup analysis of TEAEs revealed decreased incidences 
of any TEAE, drug-related grade ≥3 AEs, TEAEs leading 
to discontinuation, and serious AEs in the 600-mg and 
400-mg dose-reduced groups after the last dose reduction 
of each patient (see Supporting Table 6).
To investigate the mechanism(s) of resistance after 
olmutinib treatment, plasma samples from 27 patients 
were selected for retrospective NGS analysis. After 
cfDNA extraction and sequencing, results for 15 pa-
tients were evaluable for data analysis (see Supporting 
Fig. 2). Six patients showed loss of T790M mutation, 
whereas the actionable EGFR mutations were retained 
at PD (40%). Acquired EGFR mutations after treat-
ment were observed in 3 patients: C797S (13.3%; 
n = 2) and L718Q (6.7%; n = 1). The allele frequency 
of baseline EGFR mutations changed during treatment, 
and the C797S mutation was only detected at PD (see 
Supporting Fig. 3).
DISCUSSION
This phase 2 study of olmutinib clearly demonstrated a 
tumor response (46.3%) in patients with T790M-positive 
NSCLC who had progressed after previous EGFR-TKIs 
with or without prior chemotherapy. Efficacy was unaf-
fected by the presence of brain metastases at baseline, by 
a dosage reduction from 800 to 600 mg daily, or by the 
number of previous lines of chemotherapy. Overall, the 
olmutinib ORR (regardless of confirmation) was 51.9%, 
the median DOR was 12.7 months, and the median PFS 
was 9.4 months, which compare favorably with those of 
earlier EGFR-TKIs29-34 but fall short of the outcomes 
obtained with osimertinib in AURA3 (ClinicalTrials.gov 
number NCT02151981).35
Although almost 40% of patients required AE-
related dose reductions, the safety and tolerability of 
olmutinib were generally predictable and manageable 
during the study, with gastrointestinal, skin, and subcu-
taneous tissue disorders the most common TEAEs. The 
Figure 2. This is a waterfall plot of the maximum percentage of tumor shrinkage (determined by independent review). CR indicates 
complete response, NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease. *Fifteen of 162 patients who 
had no tumor shrinkage results after treatment are not presented in the figure; their best overall responses were non-CR/non-PD (2 
patients), PD (2 patients), and not evaluable (11 patients).
the Greatest 
once daily 
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most frequent drug-related AEs (occurring in ≥20% 
of patients) were rash, palmar-plantar erythrodysesthe-
sia syndrome, diarrhea, increased alanine aminotrans-
ferase, hyperkeratosis, and vomiting. Thirty patients 
had drug-related serious AEs, which most frequently 
comprised diarrhea and pyrexia. Twelve patients had 
TEAEs that led to death but, with the exception of 1 
case of TEN, none were considered to be drug-related. 
Although hyperkeratosis and palmar-plantar erythro-
dysesthesia syndrome tended to occur more frequently 
with olmutinib compared with other EGFR-TKIs (see 
Supporting Fig. 4),36 these events were generally tolera-
ble and manageable.
Cases of severe skin reactions (ie, Stevens-Johnson 
syndrome and TEN) have been observed in 3 patients 
treated with olmutinib, including 1 fatal case of TEN as-
sociated with olmutinib 35 days after the last dose in the 
study, in which the patient then developed septic shock 
and renal failure, resulting in death. All 3 cases were treated 
with olmutinib 800 mg daily. The mechanism underlying 
drug-induced Stevens-Johnson syndrome/TEN is consid-
ered to be a delayed-type hypersensitivity reaction. However, 
previous studies have reported a potential association be-
tween specific human leukocyte antigen (HLA) genotype 
and drug-induced hypersensitivity reactions for abaca-
vir-HLA-B*5701 and carbamazepine-HLA-B*1502.37
It is noteworthy that most (approximately 90%) 
enrolled patients were Asian, reflecting the natural his-
tory of NSCLC, all of whom had the T790M mutation. 
Moreover, in our study, an olmutinib dosage reduction 
from 800 to 600 mg daily did not appear to compro-
mise efficacy but was associated with a reduced incidence 
of TEAEs. The efficacy and safety of olmutinib 600 mg 
daily in T790M-positive NSCLC was planned to be fur-
ther investigated in a phase 1b trial to determine the op-
timal dose; however, as discussed below, the planned trial 
has not been conducted.
In our exploratory cfDNA NGS analysis, known 
EGFR mutations, such as loss of T790M, acquired 
C797S, and atypical L718Q, that also affect the activity 
of other third-generation EGFR TKIs38-40 were observed 
in olmutinib-treated samples. The variants and incidence 
of these EGFR mutations are similar to those in osim-
ertinib-treated patients.41 Other uncommon EGFR mu-
tations or amplification of driver genes (eg, MET, EGFR) 
were not detected in this analysis. This may reflect the 
small evaluable data set (samples were limited to cases in 
which optional patient consent had been obtained) and 
the limitations of cfDNA NGS to identify copy number 
alterations and, as such, limit the ability to draw clear con-
clusions. In the case of patients who lost the T790M mu-
tation after treatment, several commutations of off-target 
genes were observed in an intrinsic or acquired manner. 
However, these mutations were mostly benign or were 
unknown functional variants (data not shown).
On the basis of the results from an earlier phase 
1/2 study in Korean patients,24 olmutinib was granted 
breakthrough therapy designation for NSCLC by the 
US Food and Drug Administration in December 2015. 
At that time, the initial profile of olmutinib, including 
target selectivity, was comparable to that of third-gen-
eration EMSIs (eg, rocelitinib, naquotinib, and nazarti-
nib), which were terminated early. However, based on 
outcomes obtained in the current global trial, it appears 
that olmutinib was less selective than originally antici-
pated compared with osimertinib based on in vitro kinase 
selectivity (EGFR wild-type/T790M); and, eventually, 
olmutinib was also terminated because this current global 
trial reported inferior results in terms of safety and effi-
cacy profiles compared with the outcomes obtained with 
osimertinib in the AURA3 trial.35
In summary, to our knowledge, this global phase 2 
study is the largest prospective study of olmutinib in pa-
tients with locally advanced or metastatic NSCLC who had 
PD with T790M mutations after at least 1 line of EGFR-
TKI therapy. Efficacy and safety data from this analysis 
highlight that olmutinib 600 to 800 mg once daily has 
meaningful clinical activity with a largely predictable safety 
profile in patients with T790M-positive NSCLC who had 
received previous EGFR-TKI therapy. However, based on 
TABLE 3. The Most Common Drug-Related 
Treatment-Emergent Adverse Event for the Safety 
Set, Incidence ≥20%a
Preferred Term




All drug-related TEAEs 152 (93.8) 78 (48.2)
Diarrhea 62 (38.3) 5 (3.1)
Nausea 44 (27.2) 1 (0.6)
Hyperkeratosis 43 (26.5) 4 (2.5)
Rash 43 (26.5) 7 (4.3)
Skin exfoliation 38 (23.5) 1 (0.6)
Vomiting 37 (22.8) 3 (1.9)
Palmar-plantar erythro-
dysesthesia syndrome
35 (21.6) 7 (4.3)
Increased alanine 
aminotransferase
33 (20.4) 5 (3.1)
Abbreviation: TEAEs, treatment-emergent adverse events.
aOne case of fatal toxic epidermal necrolysis was reported, and 2 cases of 
grade 3 interstitial lung disease (ILD) were reported. (ILD/pneumonitis, ILD-
like events).
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an assessment of the competitive landscape of evolving 
EMSI treatment options, the development of olmutinib 
to treat patients with NSCLC has since been discontin-
ued. While recognizing that large, multicenter studies with 
long-term follow-up are required for new drug develop-
ment, early outcomes from the olmutinib studies are quite 
promising; in recent times, safety and risk/benefit concerns 
have resulted in the discontinued clinical development of 
several other third-generation EGFR-TKIs, such as rocile-
tinib, naquotinib, nazartinib, and canertinib.42
FUNDING SUPPORT
This study was funded by Hanmi Pharmaceutical Company, Ltd.
CONFLICT OF INTEREST DISCLOSURES
Keunchil Park reports personal fees from Hanmi Pharmaceutical Company, 
Ltd, during the conduct of the study; grants from MSD Pharmaceuticals, 
outside the submitted work; and personal fees from AbbVie, Amgen, 
AstraZeneca, BluePrint Medicines, Bristol-Myers Squibb, Boehringer-
Ingelheim, Daiichi Sankyo, Eisai, Eli Lilly, JNJ, Merck KGaA, MSD 
Pharmaceuticals, Puma Biotechnology, and Takeda, outside the submit-
ted work. Pasi A. Jänne reports other support from Hanmi Pharmaceutical 
Company, Ltd, during the conduct of the study; grants from Boehringer-
Ingelheim, Eli Lilly, Daiichi Sankyo, Takeda Oncology, outside the submit-
ted work; personal fees from AstraZeneca, Boehringer-Ingelheim, Pfizer, 
Roche/Genentech, Chugai Pharmaceuticals, Ignyta, Loxo Oncology, Eli 
Lilly, SFJ Pharmaceuticals, Voronoi, Daiichi Sankyo, Biocartis, Novartis, 
Sanofi Oncology, Takeda Oncology, Mirati Therapeutics, Transcenta, 
Silicon Therapeutics, Syndax, Astellas, PUMA, and Revolution Medicines, 
outside the submitted work; and postmarketing royalties from a Dana-
Farber Cancer Center–owned patent (EGFR Mutations) licensed to 
Lab Corp. Dong-Wan Kim reports grants and nonfinancial support 
from Hanmi Pharmaceutical Company, Ltd, during the conduct of the 
study; institutional grants from Alpha Biopharm, Amgen, AstraZeneca/
Medimmune, Boehringer-Ingelheim, Daiichi-Sankyo, Janssen, Meurs, 
Mirati Therapeutics, MSD Pharmaceuticals, Novartis, Ono Pharmaceutical, 
Pfizer, Roche/Genentech, Takeda, TP Therapeutics, Xcovery, and Yuhan, 
outside the submitted work; and nonfinancial support from Amgen and 
Daiichi-Sankyo, outside the submitted work. Ji-Youn Han reports research 
funding from Ono Pharmaceutical, Pfizer, Roche, and Takeda, outside the 
submitted work; and personal fees from AstraZeneca, Bristol-Myers Squibb, 
MSD Pharmaceuticals, Roche, Eli Lilly, MSD Oncology, Novartis, Pfizer, 
and Takeda, outside the submitted work. Dae Ho Lee reports personal fees 
from AbbVie, AstraZeneca, Boehringer-Ingelheim, Takeda, Bristol-Myers 
Squibb, ChongKunDang, CJ Healthcare, Eli Lilly, Janssen, Merck, MSD 
Pharmaceuticals, Mundipharma, Novartis, Ono Pharmaceutical, Pfizer, 
Roche, Samyang Biopharm, ST Cube, GreenCross, and Genexine, out-
side the submitted work. Byoung Chul Cho reports research funding from 
Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions 
Oncology, Janssen, Yuhan, Ono Pharmaceutical, Dizal Pharma, MSD 
Pharmaceuticals, AbbVie, Medpacto, GI Innovation, Eli Lilly, Blueprint 
Medicines, and Interpark Bio Convergence Corporation, outside the submit-
ted work; personal fees from Novartis, AstraZeneca, Boehringer-Ingelheim, 
Roche, Bristol-Myers Squibb, Ono Pharmaceutical, Yuhan, Pfizer, Eli 
Lilly, Janssen, Takeda, MSD Pharmaceuticals, Medpacto, Blueprint 
Medicines, TheraCanVac Inc, Gencurix Inc, Bridgebio Therapeutics, Cyrus 
Therapeutics, Interpark Bio Convergence Corp, KANAPH Therapeutic 
Inc, and Guardant Health, outside the submitted work; stock ownership 
in TheraCanVac Inc, Gencurix Inc, Bridgebio Therapeutics, and KANAPH 
Therapeutic Inc; is the founder of DAAN Biotherapeutics; receives royal-
ties from Champions Oncology; and is a member the boards of Gencurix 
Inc and Interpark Bio Convergence Corporation, outside the submitted 
work. Yong Kek Pang reports other support from Hanmi Pharmaceutical 
Company, during the course of the study. Enriqueta Felip reports per-
sonal fees from AbbVie, Amgen, AstraZeneca, Bayer, Blueprint Medicines, 
Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Glaxo-Smith-Kline, 
Janssen, Medscape, Merck KGaA, MSD Pharmaceuticals, Novartis, Roche, 
Peervoice, Pfizer, Prime Oncology, Puma Biotechnology, Roche, Sanofi 
Genzyme, Springer, Takeda, and Touchime, outside the submitted work; 
grants from Grant for Oncology Innovation (GOI) and Fundacion Merck 
Salud, outside the submitted work; and is an independent member of the 
board of Grifols. Hyunjin Kim, Eunhye Baek, and Young Su Noh are em-
ployees of Hanmi Pharmaceutical Company, Ltd. Ming-Fang Wu, Jong-
Seok Lee, and Chong-Jen Yu made no disclosures.
AUTHOR CONTRIBUTIONS
Keunchil Park: Study design, data acquisition, statistical analysis, arti-
cle preparation, writing, and approval. Pasi A. Jӓnne, Dong-Wan Kim, 
Ji-Youn Han, Ming-Fang Wu, Jong-Seok Lee, Jin-Hyoung Kang, Dae 
Ho Lee, Byoung Chul Cho, Chong-Jen Yu, Yong Kek Pang, Enriqueta 
Felip: Patient enrolment. Hyunjin Kim: Biomarker data analysis and writ-
ing. Eunhye Baek: Data acquisition and statistical analysis. Young Su Noh: 
Article preparation and writing.
REFERENCES
 1. World Health Organization. GLOBOCAN 2012: Estimated Cancer 
Incidence, Mortality and Prevalence Worldwide in 2012. International 
Agency for Research on Cancer; 2012. Accessed April 8, 2020. http://
globo can.iarc.fr/Defau lt.aspx
 2. American Cancer Society. Cancer Facts and Figures 2015. American 
Cancer Society; 2015. Accessed 8 April 2020. https://www.cancer.
org/conte nt/dam/cance r-org/resea rch/cance r-facts -and-stati stics/ 
annua l-cance r-facts -and-figur es/2015/cance r-facts -and-figur es-
2015.pdf
 3. Adjei AA. Epidermal growth factor receptor tyrosine kinase inhibitors 
in cancer therapy. Drugs Future. 2001;26:1087-1092.
 4. Renhowe PA. Inhibitors of growth factor receptor kinase-dependent 
signaling pathways in anticancer chemotherapy—clinical progress. 
Curr Opin Drug Discov Devel. 2002;5:214-224.
 5. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral 
epidermal growth factor receptor-tyrosine kinase inhibitor, is well tol-
erated and active in patients with solid, malignant tumors: results of a 
phase I trial. J Clin Oncol. 2002;20:2240-2250.
 6. Ciardiello F, Tortora G. A novel approach in the treatment of can-
cer: targeting the epidermal growth factor receptor. Clin Cancer Res. 
2001;7:2958-2970.
 7. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin- 
paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:  
947-957.
 8. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemother-
apy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 
2010;362:2380-2388.
 9. Janne PA, Wang X, Socinski MA, et al. Randomized phase II trial of 
erlotinib alone or with carboplatin and paclitaxel in patients who were 
never or light former smokers with advanced lung adenocarcinoma: 
CALGB 30406 trial. J Clin Oncol. 2012;30:2063-2069.
 10. Arcila ME, Oxnard GR, Nafa K, et al. Rebiopsy of lung cancer patients 
with acquired resistance to EGFR inhibitors and enhanced detection 
of the T790M mutation using a locked nucleic acid-based assay. Clin 
Cancer Res. 2011;17:1169-1180.
 11. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and re-
sistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 
2005;352:786-792.
 12. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal 
growth factor receptor tyrosine kinase inhibitors in non-small-cell lung 
cancers dependent on the epidermal growth factor receptor pathway. 
Clin Lung Cancer. 2009;10:281-289.
 13. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adeno-
carcinomas to gefitinib or erlotinib is associated with a second muta-
tion in the EGFR kinase domain. PLoS Med. 2005;2:e73.
 14. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and his-
tological evolution of lung cancers acquiring resistance to EGFR inhib-
itors. Sci Transl Med. 2011;3:75ra26.
Original Article
1416 Cancer  May 1, 2021
 15. Cheng L, Alexander RE, Maclennan GT, et al. Molecular pathol-
ogy of lung cancer: key to personalized medicine. Mod Pathol. 
2012;25:347-369.
 16. Kohno T, Nakaoku T, Tsuta K, et al. Beyond ALK-RET, ROS1 
and other oncogene fusions in lung cancer. Transl Lung Cancer Res. 
2015;4:156-164.
 17. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-
mutant non-small-cell lung cancer. Nat Rev Cancer. 2010;10:760-774.
 18. Janne PA, Boss DS, Camidge DR, et al. Phase I dose-escalation study 
of the pan-HER inhibitor, PF299804, in patients with advanced ma-
lignant solid tumors. Clin Cancer Res. 2011;17:1131-1139.
 19. Yap TA, Vidal L, Adam J, et al. Phase I trial of the irreversible EGFR 
and HER2 kinase inhibitor BIBW 2992 in patients with advanced 
solid tumors. J Clin Oncol. 2010;28:3965-3972.
 20. Liao BC, Lin CC, Lee JH, Yang JC. Update on recent preclinical and 
clinical studies of T790M mutant-specific irreversible epidermal growth 
factor receptor tyrosine kinase inhibitors. J Biomed Sci. 2016;23:86.
 21. Kim ES. Olmutinib: first global approval. Drugs. 2016;76:  
1153-1157.
 22. Lee KO, Cha MY, Kim M, et al. Discovery of HM61713 as an orally 
available and mutant EGFR selective inhibitor [abstract LB-100]. In: 
Proceedings of the 105th Annual Meeting of the American Association 
for Cancer Research; April 5-9, 2014; San Diego, California. Accessed 
April 8, 2020. http://www.abstr actso nline.com/Plan/ViewA bstra ct.as-
px?sKey=c3946 1c2-0d62-47b9-b9fb-14d45 60ae9 4e%26cKe y=db68f 
dfa-da87-4273-8ce6-17c7b 72aab ad%26mKe y=%257b6 FFE14 
46-A164-476A-92E7-C2644 6874D 93%257d
 23. Noh YS, Yoon S, Kim SR, Lee KT, Jang IJ. A safety, pharmacokinetic, 
pharmacogenomic and population pharmacokinetic analysis of the 
third-generation EGFR TKI, olmutinib (HM61713), after single oral 
administration in healthy volunteers. Basic Clin Pharmacol Toxicol. 
2019;125:370-381.
 24. Kim DW, Lee DH, Han JY, et al. Safety, tolerability, and anti-tumor 
activity of olmutinib in non-small cell lung cancer with T790M muta-
tion: a single arm, open label, phase 1/2 trial. Lung Cancer. 2019;135:  
66-72.
 25. Park K, Lee JS, Lee KH, et al. BI 1482694 (HM61713), an EGFR 
mutant-specific inhibitor, in T790M+ NSCLC: efficacy and safety at 
the RP2D [abstract]. J Clin Oncol. 2016;34(suppl):9055.
 26. Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation 
Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur 
J Cancer. 2009;45:228-247.
 27. Simon R. Optimal two-stage designs for phase II clinical trials. Control 
Clin Trials. 1989;10:1-10.
 28. Johnson JR, Ning YM, Farrell A, Justice R, Keegan P, Pazdur R. 
Accelerated approval of oncology products: the Food and Drug 
Administration experience. J Natl Cancer Inst. 2011;103:636-644.
 29. Horiike A, Yamamoto N, Tanaka H, et al. Phase II study of erlotinib 
for acquired resistance to gefitinib in patients with advanced non-small 
cell lung cancer. Anticancer Res. 2014;34:1975-1981.
 30. Sequist LV, Besse B, Lynch TJ, et al. Neratinib, an irreversible pan-
ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in 
patients with advanced non-small-cell lung cancer. J Clin Oncol. 
2010;28:3076-3083.
 31. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for 
patients with advanced, metastatic non-small-cell lung cancer after 
failure of erlotinib, gefitinib, or both, and one or two lines of chemo-
therapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 
2012;13:528-538.
 32. Katakami N, Atagi S, Goto K, et al. LUX-Lung 4: a phase II trial of 
afatinib in patients with advanced non-small-cell lung cancer who pro-
gressed during prior treatment with erlotinib, gefitinib, or both. J Clin 
Oncol. 2013;31:3335-3341.
 33. Janjigian YY, Smit EF, Groen HJ, et al. Dual inhibition of EGFR with 
afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant 
lung cancer with and without T790M mutations. Cancer Discov. 
2014;4:1036-1045.
 34. Soria JC, Wu YL, Nakagawa K, et al. Gefitinib plus chemotherapy 
versus placebo plus chemotherapy in EGFR-mutation-positive non-
small-cell lung cancer after progression on first-line gefitinib (IMPRESS): 
a phase 3 randomised trial. Lancet Oncol. 2015;16:990-998.
 35. Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in 
EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629-640.
 36. Chen KL, Cho YT, Yang CW, et al. Olmutinib-induced palmoplantar 
keratoderma. Br J Dermatol. 2018;178:e129-e131.
 37. Fan WL, Shiao MS, Hui RC, et al. HLA association with drug-induced 
adverse reactions. J Immunol Res. 2017;2017:3186328.
 38. Chabon JJ, Simmons AD, Lovejoy AF, et al. Circulating tumour DNA 
profiling reveals heterogeneity of EGFR inhibitor resistance mecha-
nisms in lung cancer patients. Nat Commun. 2016;7:11815.
 39. Yu HA, Tian SK, Drilon AE, et al. Acquired resistance of EGFR-
mutant lung cancer to a T790M-specific EGFR inhibitor: emergence 
of a third mutation (C797S) in the EGFR tyrosine kinase domain. 
JAMA Oncol. 2015;1:982-984.
 40. Bersanelli M, Minari R, Bordi P, et al. L718Q mutation as new mech-
anism of acquired resistance to AZD9291 in EGFR-mutated NSCLC. 
J Thorac Oncol. 2016;11:e121-e123.
 41. Papadimitrakopoulou VA, Wu YL, Han JY, et al. Analysis of resis-
tance mechanisms to osimertinib in patients with EGFR T790M ad-
vanced NSCLC from the AURA3 study [abstract LBA51]. Ann Oncol. 
2018;29(suppl 8):mdy424.064.
 42. Shah RR, Shah DR. Safety and tolerability of epidermal growth fac-
tor receptor (EGFR) tyrosine kinase inhibitors in oncology. Drug Saf. 
2019;42:181-198.
